Clinical-stage biopharmaceutical company Lantern Pharma (NASDAQ: LTRN) announced on Wednesday that it will present promising preclinical results for LP-184 at The Immuno-Oncology Summit 2024 in Philadelphia.

Data from collaborative research with Drs Yong Du and Shiaw-Yih (Phoebus) Lin at MD Anderson demonstrate LP-184's ability to synergise with checkpoint inhibitors and resensitise tumors resistant to Anti-PD1 therapies.

The findings, to be presented in poster #P17 titled 'LP-184, a Novel Acylfulvene, Sensitizes Immuno-Refractory Triple Negative Breast Cancers (TNBCs) to Anti-PD1 Therapy by Affecting the Tumor Microenvironment', indicate that LP-184 enhances anti-PD1 responses in non-hypermutated, immunotherapy-resistant TNBC models. The compound appears to convert 'cold' tumors into 'hot' ones by modulating T cell activity and reducing M2 macrophages, which are linked to drug resistance and tumor cell proliferation. Combining LP-184 with anti-PD1 agents yielded superior anti-tumor effects compared to single-agent therapies.

Currently, LP-184 is undergoing a Phase 1 trial (NCT05933265) to determine its maximum tolerated dose and safety profile in advanced recurrent solid tumors, including TNBC.

Lantern Pharma's AI-driven platform, RADR, leverages extensive data and machine learning to advance oncology drug discovery. The company's development pipeline, which includes both solid and blood cancer therapies, is projected to have a market potential exceeding USD15bn. Lantern Pharma's progress from initial AI insights to clinical trials typically spans 2-3 years and costs USD1.0-2.5m per program.